Global Gout Therapeutics Market Revenue Grows at a CAGR of 6.57%

Straits Research released its highly anticipated report, “Global Gout Therapeutics Market Size & Outlook, 2026-2034”. According to Straits Research, the market size is valued at USD 3.05 billion in 2025 and is projected to expand to USD 5.40 billion by 2034, registering a compound annual growth rate (CAGR) of 6.57%.

Market Dynamics

The global gout therapeutics market is experiencing steady growth, primarily driven by the rising prevalence of gout worldwide, closely linked to increasing cases of obesity, hypertension, diabetes, and aging populations. Changes in dietary habits, higher alcohol consumption, and sedentary lifestyles have contributed to a growing patient pool. Additionally, improved disease awareness and better diagnostic rates have led to earlier initiation of treatment, increasing long-term demand for urate lowering therapies and anti-inflammatory drugs. Furthermore, the introduction of advanced treatment options, including biologics for chronic and refractory gout, has strengthened physician confidence and expanded treatment adoption across hospital and specialty care settings.

Despite this, the market faces a key restraint in the form of high treatment costs associated with advanced and biologic gout therapies. This limits accessibility for patients and places a financial burden on healthcare systems. Reimbursement challenges and strict payer approval criteria further restrict widespread uptake of premium therapies, slowing market penetration in cost-sensitive regions.

On the other hand, a major opportunity lies in the development of novel targeted and long-acting gout therapies, including urate lowering agents and combination treatments. Ongoing research focused on improving efficacy, reducing flare frequency, and enhancing patient compliance is expected to transform disease management. Moreover, expanding healthcare infrastructure and increasing clinical research activity in emerging markets provide manufacturers with opportunities to reach underserved populations and strengthen their global presence.

Key Highlights

• Drug Class: The xanthine oxidase inhibitors segment dominated the market with a revenue share of 43.78% in 2025.
• Disease Type: The chronic tophaceous segment is estimated to grow at the fastest pace with a CAGR of 7.32% during 2026-2034.
• Distribution Channel : The drug stores & retail pharmacies segment dominated the market in 2025 with a revenue share of 61.25%.
• Regional Insights: North America accounted for 41.13% market share, driven by early uptake of advanced urate lowering drugs.

Market Segments

1. By Drug Class (2026-2034)
   1. Xanthine Oxidase Inhibitors
   2. NSAIDs
   3. Corticosteroids
   4. Uricosurics
   5. Recombinant Uricase
   6. Interleukin-1 Inhibitors
   7. Others
2. By Disease Type (2026-2034)
   1. Acute 
   2. Intercritical 
   3. Chronic tophaceous
   4. Others
3. By Distribution Channel (2026-2034)
   1. Hospital Pharmacies
   2. Drug Stores & Retail Pharmacies
   3. Online Pharmacies
4. By Region (2026-2034)
   1. North America
   2. Europe
   3. Asia Pacific
   4. Latin America
   5. The Middle East and Africa